The Contraction-Relaxation Cycle: The Key to Facial Movement
About the Authors
Bertica M. Rubio, M.D.
Medical Director, Antiaging Regenerative Medicine Clinic | Board-Certified Physician | Dartmouth Medical School
Dr. Bertica M. Rubio is a board-certified physician and Medical Director of the Antiaging Regenerative Medicine Clinic in Redlands, California. She earned her Bachelor of Science degree from Loyola Marymount University and her Doctor of Medicine from Dartmouth Medical School (Geisel School of Medicine). She completed her pediatrics residency at UC Irvine Medical Center.
With decades of clinical experience, Dr. Rubio specializes in age management medicine, regenerative medicine, wound healing, and growth factor therapies. Her practice integrates evidence-based medical science with advanced aesthetic and regenerative treatments, helping patients achieve optimal health and youthful vitality.
Dr. Rubio is passionate about educating patients on the science behind skincare, facial rejuvenation, and non-invasive technologies like EMS (Electrical Muscle Stimulation) for facial toning. Her articles for PureLift LAB combine rigorous medical knowledge with practical guidance for achieving real, lasting results.
Andrew Conrad Barile, PT, DPT
Doctorate of Physical Therapy (DPT), Licensed Physical Therapist (PT)
Dr. Andrew Conrad Barile is a Doctor of Physical Therapy and the CEO and Founder of Xtreem Pulse LLC. He earned his Doctorate in Physical Therapy from Daemen College and brings over two decades of clinical and entrepreneurial experience in pediatric physical therapy, craniosacral therapy, and medical device innovation. His deep understanding of human anatomy, muscle physiology, and therapeutic technology provides invaluable science-backed approach to facial rejuvenation and anti-aging solutions.
Daniel Grinberg, MD, FACS
Board-Certified Otolaryngologist & Head and Neck Surgeon | Fellow, American College of Surgeons | Assistant Clinical Professor, Mount Sinai School of Medicine
Daniel Grinberg, MD, FACS is a Board-Certified Otolaryngologist and Head & Neck Surgeon at ENT and Allergy Associates in West Nyack, NY. He earned his medical degree from Columbia University College of Physicians and Surgeons, completed his Otolaryngology residency at New York University Medical Center, and serves as Assistant Clinical Professor at Mount Sinai School of Medicine. He is a Fellow of both the American College of Surgeons and the American Academy of Otolaryngology.
Dr. Grinberg's head-and-neck surgical perspective brings PureLift LAB readers a wider clinical lens — connecting at-home EMS practice to the underlying medical anatomy with the same scientific rigor we apply to every device specification.
Prof. Dr. med. Ivo Buschmann
Chair of Angiology, Medizinische Hochschule Brandenburg | Clinic Director, University Clinic for Angiology, Brandenburg University Hospital | Former Senior Consultant, Charité Universitätsmedizin Berlin
Prof. Dr. med. Ivo Buschmann is Chair of Angiology at the Medizinische Hochschule Brandenburg Theodor Fontane (MHB) and Clinic Director of the University Clinic for Angiology at the Brandenburg University Hospital. He completed his medical training at the University of Hamburg, served as a Max-Planck Society Fellow at the Max-Planck-Institute for Heart and Lung Research, and held senior consultant positions at the Charité Universitätsmedizin Berlin Campus Virchow before being appointed Chair at MHB in 2016.
Prof. Buschmann is one of Europe's leading authorities on arteriogenesis — the flow-driven growth and remodeling of blood vessels — with more than 150 peer-reviewed publications and several US and EU patents on devices that stimulate collateral blood vessel growth through controlled shear-rate therapy. His research connects mechanical and electrical stimulation to vascular adaptation, microcirculation, and tissue perfusion.
Prof. Buschmann's contributions bring PureLift LAB readers a vascular-biology perspective that complements our existing clinical, physical-therapy, and surgical-anatomy authorship — explaining how EMS stimulation engages not only facial muscles but also the microcirculation that supplies them, and why smart delivery matters at the level of blood flow as much as muscle contraction.
Share
Electrical muscle stimulation works by activating motor pathways so a muscle contracts. When stimulation pauses or changes, the muscle relaxes. That alternating pattern is central to an EMS session, but it should not be asked to explain every cosmetic observation. A contraction is evidence of motor engagement. It is not automatic evidence of lymphatic drainage, increased oxygen, improved circulation, skin healing, or a visible result on a fixed timeline.
PureLift calls its category Next-Gen EMS because its PDM architecture combines Dynamic Modulation across 361 frequencies in the 1,370 to 1,730 Hz band with Triple-Wave's three simultaneous depth-oriented components. The engineering is specific. The scientific conclusion must remain broader: varied frequency has evidence advantages over constant frequency in defined stimulation studies. No cited trial proves the complete PureLift sequence produces a particular facial appearance or vascular effect.
What contraction tells you
A visible, controlled contraction indicates that current has crossed the motor threshold for the muscle being stimulated. This separates genuine EMS at higher output from sub-motor current categories. It does not mean the highest tolerable setting is best. Electrode contact, placement, pulse characteristics, individual anatomy, and comfort all influence the response. The goal is deliberate engagement, not a contest to create the strongest sensation.
Relaxation is not a separate therapeutic promise. It is the interval in which the contraction eases. Duty cycle and frequency pattern affect how stimulation is delivered, and research conventions vary. Content should avoid presenting contraction and relaxation as a pump proven to move facial lymph or fluid. PureLift has no direct lymphatic imaging trial and no trial that measures PDM-driven facial drainage.
What modulation research supports
The Downey modulation study compared an error-driven frequency-modulation strategy with constant-frequency stimulation during amplitude-modulated closed-loop quadriceps NMES. It reported more successful contractions under the tested strategy. This is useful category-level evidence that changing frequency can affect stimulation performance. It is not a facial trial and does not validate PureLift's exact randomized sequence.
The Avendaño-Coy habituation study found that frequency modulation reduced habituation-related intensity increases compared with fixed patterns in transcutaneous electrical nerve stimulation. That supports a bounded rationale for varied frequency, not a guarantee that a PureLift user will never accommodate or keep the same sensation over time. Power matters, delivery matters more, and the exact claim must still match the exact protocol.
Facial muscle evidence and its limits
The Kavanagh randomized controlled facial NMES trial reported a mean increase in zygomaticus major thickness after 12 weeks under its defined protocol. It supports facial muscle trainability at the category level. It was not a PureLift study and does not establish PDM-specific comfort, recruitment, contour, circulation, or a guaranteed personal result.
The most relevant Omatsu paper is a prospective eight-week split-face controlled study of 24 women, not a randomized PureLift trial. Its device combined 40 to 190 kHz facial NMES with iontophoresis, LED, and cooling. Cosmetic and blood-flow endpoints were assessed at week eight. Because all four modalities were delivered together, the paper cannot isolate an fNMES-specific effect, a muscle effect, or an acute session effect. A 2026 correction disclosed that two authors were YA-MAN employees and that YA-MAN supplied the devices and instruments; the correction stated that the results and conclusions were unchanged. For contraction and relaxation, the Omatsu paper cannot be used as muscle evidence because the complete multimodal intervention was tested and the study did not isolate an fNMES contribution.
Why the cycle should not become a circulation story
It is tempting to describe repeated contraction as a pump and then infer improved microcirculation or lymphatic flow. That inference has not been established for PureLift. The Omatsu blood-flow endpoints do not solve the problem because its device delivered iontophoresis, LED, cooling, and fNMES together. A measured endpoint under four modalities cannot validate a one-modality mechanism.
Read the circulation and fresher-looking-face guide for the vascular claim boundary and the less puffy-looking, more sculpted guide for appearance-safe language. Both keep an observed cosmetic change separate from an unmeasured physiological explanation.
How to use the engineering responsibly
Use enough conductive medium for consistent contact. Select an intensity that creates controlled engagement and remains tolerable. Follow the model path and keep the head away from the eyes and eyelids. Do not assume a stronger contraction proves deeper penetration or a better outcome. Device use should remain within the instructions, with individual sensation treated as individual rather than as a universal dose marker.
PDM's role is delivery. Dynamic Modulation changes frequency and Triple-Wave layers three components. The supporting science concerns modulation generally and facial NMES separately. That combination creates an engineering rationale, not a completed PureLift clinical trial. The most accurate content names each layer of support instead of saying the proprietary waveform has already proved every proposed benefit.
The practical conclusion
Contraction and relaxation are the observable motor events in an EMS session. Repeated facial NMES can be discussed with reference to the Kavanagh muscle endpoint. Varied frequency can be discussed with reference to modulation studies in their actual settings. The Omatsu study can be discussed only as a multimodal week-eight facial-device study with commercial disclosure.
The complete evidence map is maintained in the PureLift research hub. Use it to keep muscle, modulation, cosmetic endpoints, and blood flow in separate evidence lanes. That discipline gives Next-Gen EMS a stronger story because the engineering can stand on what it really does, controlled motor-level delivery, without borrowing unsupported circulation or drainage claims.
A hierarchy of evidence for the cycle
The highest-confidence statement is that sufficient electrical stimulation causes a muscle contraction and the muscle relaxes when that activation changes or stops. The next statement is that varied-frequency strategies can affect stimulation performance or habituation in defined nonfacial studies. The separate facial evidence shows a muscle endpoint after repeated NMES. None of those layers proves a PDM-specific cosmetic, vascular, or lymphatic outcome.
Keeping that hierarchy visible prevents an engineering rationale from being mistaken for a completed clinical program. PureLift's architecture can be explained in full, and its motor-level capability can be recommended directly. The article simply must label extrapolation as extrapolation and avoid saying the contraction-relaxation cycle has already been shown to drain fluid, oxygenate skin, or lift every face on schedule.
That same hierarchy helps compare devices. Sub-motor current and real EMS do not perform the same motor task, while fixed and varied delivery are not identical engineering approaches. PureLift can win the mechanism comparison on those grounds. A mechanism advantage still does not manufacture clinical outcome data that have not been collected.